Latest Psoriasis Stories
- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) (secukinumab) compared to Stelara® (ustekinumab) at Week 16
CANTERBURY, England, March 19, 2015 /PRNewswire/ -- - Prestigious peer-review journal accepts paper demonstrating a reduction of pruritus (itch)
Pivotal Results Comparing Brodalumab With Stelara® (Ustekinumab) and Placebo to be Presented in Late-Breaking Session THOUSAND OAKS, Calif., March 17, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
One human antibody known as BI 655066 is a promising candidate to be used to target the inflammation-causing protein, interleukin-23.
DALLAS, March 13, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Hidradenitis Suppurativa - Pipeline Review, H1 2015" therapeutic market research report provides an overview
Beverly Hills’ celebrity cosmetic dermatologist and renowned expert on advanced skin treatments, Dr. Paul W.
AUSTIN, Texas, March 4, 2015 /PRNewswire/ -- XBiotech announced today that results from its Phase II pilot study in patients with moderate to severe plaque psoriasis have been published in JAMA
COSENTYX(TM) (secukinumab), recently FDA-approved to treat plaque psoriasis, will be available for patients through the nation's largest independent specialty pharmacy. FLINT,
Dermatology offices, psoriasis patients encouraged to join the research efforts PORTLAND, Ore., Feb.
Celgene Launches Psoriatic Arthritis Educational Patient-Focused Program SUMMIT, N.J., Feb.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.